TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Pharmaxis Ltd ( (AU:SNT) ) is now available.
Syntara Limited announced it has received an R&D tax incentive of A$5.6 million from the Australian Government for its eligible research and development activities in 2025. This non-dilutive funding will allow Syntara to further its drug development programs while maintaining financial flexibility, potentially impacting its operations and industry positioning positively.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited is a clinical stage drug development company focused on targeting extracellular matrix dysfunction. With expertise in amine oxidase chemistry, Syntara develops novel medicines for blood cancers and conditions linked to inflammation and fibrosis. Its lead candidate, amsulostat, is being developed for myelofibrosis and has received FDA Orphan Drug Designation. The company is also advancing studies in hypertrophic scars, keloid scars, and neurodegenerative diseases like Parkinson’s. Syntara has previously developed and sold two respiratory products, Bronchitol and Aridol, and is listed on the Australian Securities Exchange.
Average Trading Volume: 4,644,455
Technical Sentiment Signal: Sell
Current Market Cap: A$39.18M
Learn more about SNT stock on TipRanks’ Stock Analysis page.